切换至 "中华医学电子期刊资源库"

中华肾病研究电子杂志 ›› 2017, Vol. 06 ›› Issue (04) : 145 -148. doi: 10.3877/cma.j.issn.2095-3216.2017.04.001

所属专题: 文献

述评

肾病综合征的新型生物学标志物研究进展
阳晓1,(), 黄旋1, 余学清1   
  1. 1. 510080 广州,中山大学附属第一医院肾内科
  • 收稿日期:2017-05-15 出版日期:2017-08-28
  • 通信作者: 阳晓
  • 基金资助:
    国家重点研发计划项目(2016YFC0906100); 国家自然科学基金(81570614,81774069)

Advances in new biological markers of nephrotic syndrome

Xiao Yang1,(), Xuan Huang1, Xueqing Yu1   

  1. 1. Department of Nephrology, First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong 510080, China
  • Received:2017-05-15 Published:2017-08-28
  • Corresponding author: Xiao Yang
  • About author:
    Corresponding author: Yang Xiao, Email:
引用本文:

阳晓, 黄旋, 余学清. 肾病综合征的新型生物学标志物研究进展[J]. 中华肾病研究电子杂志, 2017, 06(04): 145-148.

Xiao Yang, Xuan Huang, Xueqing Yu. Advances in new biological markers of nephrotic syndrome[J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2017, 06(04): 145-148.

肾病综合征( NS)是由于肾小球基底膜损伤、肾小球滤过屏障破坏而引起血浆蛋白质大量于尿中丢失所产生的病理生理状态。临床分为原发性和继发性两大类。原发性肾病综合征(INS)多为免疫炎症介导,糖皮质激素和免疫抑制剂是其主要治疗药物。激素抵抗、激素依赖和频繁复发的NS属于难治性肾病综合征的范畴,其对药物治疗反应差,易进展至终末期肾衰竭。影响NS疗效的主要因素包括病理类型、治疗不规范、并发症等。近年来基因组学和蛋白质组学技术显示单基因突变和潜在的循环因子与NS激素抵抗相关。不同年龄阶段激素抵抗的NS患者病原学影响因素不同。因此,进一步从遗传和分子学水平探讨NS发病机制及早期预警治疗反应性的生物学标记,实现精准诊断和治疗,对提高NS疗效、减少药物毒副反应及改善预后具有重要的指导作用。

Nephrotic syndrome is a pathophysiological condition caused by dysfunction of glomerular filtration barrier, which allows the massive flow of plasma proteins into the urine. It can be divided into the primary forms and the secondary forms according to its etiology. Idiopathic nephrotic syndrome (INS) is mostly immunoinflammation-mediated. Response to steroids or other immunosuppressives, the initial mainstay of therapy, is closely related to the prognosis of this disease. Steroid-resistant NS, steroid-dependent NS, and frequently-relapsed NS all belong to the category of refractory NS. Their poor responding to immunosuppression leads to a high risk for end-stage renal failure. The main factors which affect its efficacy include histopathological patterns, substandard treatment, and complications, etc. Since the advent of next generation sequencing and proteomics techniques, advancements in genetic and molecular profiling have shown that single-gene mutations and the potential circulating factors might be involved in the mechanisms of steroid-resistant NS. And the impact of different etiologic factors across age groups represents differently. Therefore, to minimize unnecessary immunosuppression and to adapt precise treatments based on likely mechanisms, further understanding of the underlying etiology at a molecular level as well as early identification of biomarkers that predict the response to treatment or recurrences will hold great significance for the improvement of efficacy and patients′ outcomes.

[1]
Kidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group. KDIGO clinical practice guideline for glomerulonephritis [J]. Kidney Int Suppl, 2012, 2: 139-274.
[2]
McKinney PA, Feltbower RG, Brocklebank JT, et al. Time trends and ethnic patterns of childhood nephrotic syndrome in Yorkshire [J]. UK Pediatr Nephrol, 2001, 16(12): 1040-1044.
[3]
Gipson DS, Chin H, Presler TP, et al. Differential risk of remission and ESRD in childhood FSGS [J]. Pediatr Nephrol, 2006, 21(3): 344-349.
[4]
王海燕. 肾脏病学[M]. 3版,北京:人民卫生出版社,2008: 940-960.
[5]
叶任高.中西医结合肾脏病学[M].1版,北京:人民卫生出版社,2003: 155-157.
[6]
Bierzynska A, McCarthy HJ, Soderquest K, et al. Genomic and clinical profiling of a national nephrotic syndrome cohort advocates a precision medicine approach to disease management [J]. Kidney Int, 2017, 91(4): 937-947.
[7]
Sadowski CE, Lovric S, Ashraf S, et al. A single-gene cause in 29.5% of cases of steroid-resistant nephrotic syndrome [J]. J Am Soc Nephrol, 2015, 26(6): 1279-1289.
[8]
Bierzynska A, Soderquest K, Koziell A. Genes and podocytes - new insights into mechanisms of podocytopathy [J]. Front Endocrinol, 2015, 5: 226.
[9]
Ebarasi L, Ashraf S, Bierzynska A, et al. Defects of CRB2 cause steroid-resistant nephrotic syndrome [J]. Am J Human Genet, 2015, 96(6): 153-161.
[10]
Miyake N, Tsukaguchi H, Koshimizu E, et al. Biallelic mutations in nuclear pore complex subunit NUP107 cause early-childhood-onset steroid-resistant nephrotic syndrome [J]. Am J Human Genet, 2015, 97(4): 555-566.
[11]
Braun DA, Sadowski CE, Kohl S, et al. Mutations in nuclear pore genes NUP93, NUP205 and XPO5 cause steroid-resistant nephrotic syndrome [J]. Nat Genet, 2016, 48(4): 457-465.
[12]
Gee HY, Zhang F, Ashraf S, et al. KANK deficiency leads to podocyte dysfunction and nephrotic syndrome [J]. J Clin Invest, 2015, 125(6): 2375-2384.
[13]
McCarthy HJ, Bierzynska A, Wherlock M, et al. Simultaneous sequencing of 24 genes associated with steroid-resistant nephrotic syndrome [J]. Clin J Am Soc Nephrol, 2013, 8(4): 637-648.
[14]
Gee HY, Ashraf S, Wan X, et al. Mutations in EMP2 cause childhood-onset nephrotic syndrome [J]. Am J Hum Genet, 2014, 94(6): 884-890.
[15]
Becherucci F, Mazzinghi B, Provenzano A, et al. Lessons from genetics: is it time to revise the therapeutic approach to children with steroid-resistant nephrotic syndrome? [J]. J Nephrol, 2016, 29(4): 543-550.
[16]
Ulinski T. Recurrence of focal segmental glomerulosclerosis after kidney transplantation: strategies and outcome [J]. Curr Opin Organ Transplant, 2010, 15(5): 628-632.
[17]
Konigshausen E, Sellin L. Circulating permeability factors in primary focal segmental glomerulosclerosis: a review of proposed candidates [J]. Biomed Res Int, 2016, 2016: 3765608.
[18]
Reiser J, Mundel P. Danger signaling by glomerular podocytes defines a novel function of inducible B7-1 in the pathogenesis of nephrotic syndrome [J]. J Am Soc Nephrol, 2004, 15(9): 2246-2248.
[19]
Wen Q, Huang L, Luo N, et al. Proteomic profiling identifies haptoglobin as a potential serum biomarker for steroid-resistant nephrotic syndrome [J]. Am J Nephrol, 2012, 36(2): 105-113.
[20]
Kim SH, Park SJ, Han KH, et al. Pathogenesis of minimal change nephrotic syndrome: an immunological concept [J]. Korean J Pediatr, 2016, 59(9): 205-211.
[21]
Lai KW, Wei CL, Tan LK, et al. Overexpression of interleukin-13 induces minimal-change-like nephropathy in rats [J]. J Am Soc Nephrol, 2007, 18(5): 1476-1485.
[22]
Youssef DM, Elbehidy RM, Abdelhalim HS, et al. Soluble interleukine-2 receptor and MDR1 gene expression levels as inflammatory biomarkers for prediction of steroid response in children with nephrotic syndrome [J]. Iran J Kidney Dis, 2011, 5(3): 154-161.
[23]
Wei C, El Hindi S, Li J, et al. Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis [J]. Nat Med, 2011, 17(8): 952-960.
[24]
Kronbichler A, Saleem MA, Meijers B, et al. Soluble urokinase receptors in focal segmental glomerulosclerosis: a review on the scientific point of view [J]. J Immunol Res, 2016, 2016: 2068691.
[25]
Beck LH Jr, Bonegio RG, Lambeau G, et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy [J]. N Engl J Med, 2009, 361(1): 11-21.
[26]
Hofstra JM, Beck LH Jr, Beck DM, et al. Anti-phospholipase A receptor antibodies correlate with clinical status in idiopathic membranous nephropathy [J]. Clin J Am Soc Nephrol, 2011, 6(6): 1286-1291.
[27]
Hoxha E, Harendza S, Zahner G, et al. An immunofluorescence test for phospholipase-A2-receptor antibodies and its clinical usefulness in patients with membranous glomerulonephritis [J]. Nephrol Dial Transplant, 2011, 26(8): 2526-2532.
[28]
Bennett MR, Pleasant L, Haffner C, et al. A novel biomarker panel to identify steroid resistance in childhood idiopathic nephrotic syndrome [J]. Biomark Insights, 2017, 12: 1177271917695832.
[1] 智元昭, 曹璐, 窦文杰, 王琴, 张建江. 利妥昔单抗治疗儿童非复杂性激素依赖型肾病综合征疗效分析[J]. 中华妇幼临床医学杂志(电子版), 2023, 19(01): 54-60.
[2] 曾舒涵, 庾楠楠, 应道静, 陈丽植, 容丽萍, 莫樱, 蒋小云. 激素敏感型原发性肾病综合征患儿激素治疗巩固维持阶段不同减量方案比较[J]. 中华妇幼临床医学杂志(电子版), 2022, 18(04): 468-475.
[3] 尚慧, 陶于洪. 维生素D及其类似物对肾脏病患儿的保护作用[J]. 中华妇幼临床医学杂志(电子版), 2021, 17(05): 497-502.
[4] 邓会英, 李颖杰, 陈椰, 杨华彬, 钟发展, 邓慧. 儿童不典型急性链球菌感染后肾小球肾炎临床分析[J]. 中华妇幼临床医学杂志(电子版), 2021, 17(02): 243-248.
[5] 刘光磊, 杨军, 李成荣. 儿童特发性肾病综合征低IgG血症机制:哺乳动物雷帕霉素靶蛋白过表达对滤泡辅助性T细胞数量的可能影响[J]. 中华妇幼临床医学杂志(电子版), 2020, 16(02): 171-180.
[6] 胡伟涛, 李星瀚, 刘琦, 孟贺, 马琳, 邓永强. 微小核糖核酸-21在口腔鳞状细胞癌中作为生物学标志物的研究进展[J]. 中华口腔医学研究杂志(电子版), 2022, 16(05): 328-332.
[7] 贾孝娟, 陈斌, 张巍巍, 谢方瑜, 李文利, 张一, 姜大磊, 付来琳, 王尧, 解祥军. 磷脂酰肌醇蛋白聚糖1联合肿瘤标志物检测对胰腺癌的诊断价值[J]. 中华普通外科学文献(电子版), 2021, 15(04): 263-268.
[8] 甘丽杏, 郑永超. 阿奇霉素对COPD急性发作期患者组蛋白去乙酰化酶2表达影响[J]. 中华肺部疾病杂志(电子版), 2021, 14(03): 321-324.
[9] 甘丽杏, 熊维宁, 郭雪君. 慢性阻塞性肺疾病炎症因子与组蛋白去乙酰化酶2表达的临床意义[J]. 中华肺部疾病杂志(电子版), 2021, 14(02): 195-197.
[10] 李红芳, 赵小环, 王丽萍, 许晓燕, 孙高高. 子宫颈癌细胞学新型生物标志、诊断标志物的筛选和开发现状[J]. 中华细胞与干细胞杂志(电子版), 2019, 09(06): 375-384.
[11] 陈奇峰, 黄涛, 沈露俊, 李旺, 吴沛宏. ASTN1表达与肝细胞癌侵袭转移及预后的关系[J]. 中华肝脏外科手术学电子杂志, 2020, 09(03): 278-282.
[12] 王东, 张亚伟, 丁小桐, 倪洁. 激活素A在肾脏疾病中的作用研究进展[J]. 中华肾病研究电子杂志, 2022, 11(01): 48-51.
[13] 黄可群, 刘琳, 崔巍, 吴祥. MicroRNA调控认知功能的研究进展[J]. 中华脑科疾病与康复杂志(电子版), 2020, 10(01): 53-56.
[14] 徐玲玲, 田汉, 闻萍, 何伟春. 利妥昔单抗治疗难治性微小病变性肾病一例并文献复习[J]. 中华临床医师杂志(电子版), 2023, 17(05): 617-621.
[15] 杨恺惟, 虞巍, 宋毅. 多西他赛联合卡铂治疗转移性去势抵抗性前列腺癌的临床探索[J]. 中华临床医师杂志(电子版), 2023, 17(01): 23-27.
阅读次数
全文


摘要